Trial Profile
TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifapentine (Primary) ; Isoniazid; Moxifloxacin; Pyrazinamide
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- 27 Feb 2017 Status changed from not yet recruiting to recruiting.
- 07 Oct 2015 New trial record